Weekly Investment Analysts’ Ratings Changes for Ralliant (RAL)

Several analysts have recently updated their ratings and price targets for Ralliant (NYSE: RAL):

• 2/9/2026 – Ralliant was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
• 2/9/2026 – Ralliant had its price target lowered by analysts at Barclays PLC from $60.00 to $52.00. They now have an “overweight” rating on the stock.
• 2/6/2026 – Ralliant had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $45.00 price target on the stock.
• 2/6/2026 – Ralliant had its price target lowered by analysts at Truist Financial Corporation from $62.00 to $49.00. They now have a “buy” rating on the stock.
• 2/6/2026 – Ralliant had its price target lowered by analysts at Royal Bank Of Canada from $52.00 to $41.00. They now have a “sector perform” rating on the stock.
• 2/6/2026 – Ralliant had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $60.00 to $50.00. They now have an “outperform” rating on the stock.
• 2/6/2026 – Ralliant had its price target lowered by analysts at Citigroup Inc. from $61.00 to $51.00. They now have a “buy” rating on the stock.
• 2/6/2026 – Ralliant was upgraded by analysts at Vertical Research from a “hold” rating to a “buy” rating. They now have a $45.00 price target on the stock.
• 2/5/2026 – Ralliant was downgraded by analysts at Weiss Ratings from a “hold (c)” rating to a “sell (d)” rating.
• 1/7/2026 – Ralliant had its price target raised by analysts at Barclays PLC from $59.00 to $60.00. They now have an “overweight” rating on the stock.
• 12/29/2025 – Ralliant had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 23rd. Investors of record on Monday, March 9th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s payout ratio is presently 10.20%.

Insiders Place Their Bets

In other news, SVP Amir A. Kazmi purchased 2,545 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was bought at an average cost of $39.27 per share, with a total value of $99,942.15. Following the purchase, the senior vice president directly owned 39,699 shares of the company’s stock, valued at approximately $1,558,979.73. This trade represents a 6.85% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin E. Bryant purchased 1,250 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were acquired at an average price of $39.97 per share, for a total transaction of $49,962.50. Following the acquisition, the director directly owned 4,653 shares in the company, valued at $185,980.41. This represents a 36.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 8,145 shares of company stock valued at $332,233 over the last ninety days.

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.